Table 5.

Correlation between study parameters and adverse drug reactions using Spearman test

Significant Parameters	Correlation Coefficient(r)	P -value
Gender-number of ADRs	0.152	0.025
Gender-incidence of ADR	0.136	0.046
Gender-death	0.212	0.002
Gender-anaphylactic reactions	0.141	0.038
Gender-ecchymosis	0.169	0.012
Gender-headache	0.135	0.047
Number of ADRs-age	0.136	0.045
Number of ADRS -history of poly-pharmacy	0.212	0.002
Number of ADRs –VF	0.205	0.002
Number of ADRs – PE	0.160	0.020
Number of ADRs - hemoglobin deficiency	-0.225	0.001
Number of ADRs -allergy history	0.143	0.036
Number of ADRs - history of anti-coagulant usage	0.163	0.017
Incidence of ADRs - location of MI	0.143	0.047
Incidence of ADR – history of allergy	0.160	0.018
Incidence of ADRs- PE	0.184	0.006
Incidence of ADRs - dyslipidemia	0.174	0.010
Incidence of ADRs - EF	-0.150	0.031
location of MI - EF	-0.142	0.042
Age- EF	-0.210	0.004
location of MI - bradycardia	0.152	0.034
location of MI-tachycardia	0.183	0.012
History of polypharmacy- Incidence of ADRs	0.154	0.023
History of polypharmacy- PE	0.159	0.019
History of polypharmacy-fever	0.147	0.030
History of polypharmacy-ecchymosis	0.145	0.033
ADRs: adverse drug reactions, EF: ejection fraction, MI: myocardial infarction, PE: pulmonary embolism, VF: ventricular tachycardia.